Tesamorelin: The Only FDA-Approved Peptide for Visceral Fat — 2026 Complete Research Guide

Tesamorelin (formerly designated TH9507) is a synthetic analogue of endogenous human growth hormone-releasing hormone (GHRH), the 44-amino-acid hypothalamic peptide that stimulates the anterior pituitary to secrete growth hormone. The synthetic version is structurally identical to GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus that protects against rapid enzymatic degradation while preserving full biological activity at the GHRH receptor.

Tesamorelin's regulatory journey is distinctive. Developed by Theratechnologies (Canada), it was approved by the FDA in November 2010 under the brand name EGRIFTA specifically for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy — a metabolic complication common in HIV patients on antiretroviral therapy, characterized by preferential accumulation of visceral fat with concurrent loss of peripheral subcutaneous fat. EGRIFTA became the first and still only FDA-approved drug specifically indicated for visceral fat reduction.

In 2025, the FDA approved EGRIFTA WR (the "WR" standing for weekly release, using the F8 formulation technology), a reformulated version requiring only once-weekly subcutaneous injection rather than the original daily injection. This substantially reduces administration burden and is expected to improve adherence in clinical practice. Research peptide vendors continue to carry daily-injection tesamorelin formulations for laboratory research purposes outside the prescription context.

Visceral adipose tissue (VAT) — the fat depot surrounding the liver, pancreas, intestines, and other abdominal organs — is metabolically distinct from subcutaneous fat in ways that make it specifically dangerous. VAT is highly lipolytically active, releasing free fatty acids directly into portal circulation, where they reach the liver and drive hepatic fat accumulation, insulin resistance, and dyslipidemia. VAT is also pro-inflammatory: it secretes elevated levels of adipokines including TNF-α, IL-6, and resistin, while producing less adiponectin than subcutaneous fat. The resulting systemic inflammatory state contributes to atherosclerosis, endothelial dysfunction, and metabolic syndrome independent of total body weight.

This is why BMI is a poor predictor of cardiometabolic risk, and why waist circumference (a crude proxy for VAT) outperforms BMI in multiple cardiovascular risk models. Two individuals with identical BMI can have dramatically different visceral fat burdens and correspondingly different risk profiles. CT-based quantification of VAT is the most accurate available measurement — and it is the primary endpoint used in all three tesamorelin pivotal trials.

The reason GHRH axis stimulation specifically targets visceral fat involves receptor biology. Visceral adipocytes express significantly higher densities of GH receptors than subcutaneous adipocytes. GH acts on these receptors to activate hormone-sensitive lipase (HSL) — the enzyme responsible for triglyceride hydrolysis (lipolysis) inside fat cells. The net effect is preferential mobilization of visceral fat when GH levels are elevated, even in the absence of significant subcutaneous fat loss. This visceral selectivity is the pharmacological basis for tesamorelin's therapeutic specificity — and it cannot be replicated by generic caloric restriction or exercise, which reduce both fat depots proportionally.

Understanding why tesamorelin is preferred over direct GH administration requires understanding the pituitary feedback circuit. Endogenous GHRH is released from the hypothalamus in pulses, stimulating somatotroph cells in the anterior pituitary to secrete GH in corresponding pulses. This pulsatile pattern matters: the amplitude and frequency of GH pulses, rather than sustained tonic GH elevation, produces the optimal signal for downstream IGF-1 production and tissue effects. Pulsatile GH release also preserves the feedback inhibition loop — rising IGF-1 levels feed back to suppress both hypothalamic GHRH and pituitary GH secretion, preventing runaway GH elevation.

When exogenous GH is administered directly (as in GH replacement therapy or illicit GH use), it bypasses pituitary regulation entirely. The result is continuous, non-pulsatile GH elevation that can produce supraphysiological IGF-1 levels, suppress endogenous GH secretion through feedback, and carry the side effect risks associated with GH excess: insulin resistance, edema, carpal tunnel syndrome, and in extreme cases acromegaly-like effects. Monitoring is required.

Tesamorelin, by contrast, works at the pituitary level — it stimulates the pituitary to release its own GH in a pulsatile, regulated fashion. The feedback inhibition loop remains intact. IGF-1 rises meaningfully (a documented finding in all three pivotal trials) but within physiological ranges that preserve the natural regulatory architecture. This is mechanistically more elegant and clinically safer than direct GH administration for purposes of visceral fat reduction. The pituitary becomes an active participant in the pharmacological effect rather than being bypassed entirely.

Tesamorelin's evidence base is grounded in three Phase 3 randomized controlled trials, all using CT-measured VAT as the primary or co-primary endpoint — the most rigorous methodology available for visceral fat research.

Falutz et al. 2007 (New England Journal of Medicine) ^[1] was the landmark study that established tesamorelin's clinical viability. In 391 HIV-infected patients with excess abdominal fat randomized to tesamorelin 2mg/day subcutaneously or placebo for 26 weeks:

• VAT reduction: approximately 15% in the tesamorelin group vs essentially no change in placebo
• Trunk fat (total) reduced significantly
• LDL cholesterol improved modestly
• IGF-1 rose significantly, confirming GH axis activation
• Well-tolerated overall; injection site reactions were the most common adverse event

Falutz et al. 2010 (AIDS) ^[2] followed patients from the original trial in a 26-week extension, providing the first long-term data:

• VAT reduction was sustained in patients continuing tesamorelin (~15% sustained reduction at 52 weeks)
• Patients who switched from tesamorelin to placebo showed VAT returning toward baseline over the extension period — confirming that ongoing administration is required to maintain visceral fat reduction
• Lean body mass was preserved (no muscle wasting), and quality-of-life scores improved

Stanley et al. 2014 (JAMA) ^[3] added a critical finding to the evidence base: liver fat. In 155 HIV-infected patients with abdominal fat accumulation, tesamorelin 2mg/day for 26 weeks produced:

• VAT reduction: approximately 18% — the largest of the three pivotal trials
• Hepatic fat reduction: approximately 18% measured by MRI-PDFF (proton density fat fraction) — a finding with direct relevance to NAFLD research
• IGF-1 elevated as expected; GH axis clearly stimulated

The consistent finding across all three trials: when tesamorelin is stopped, visceral fat returns toward baseline. This is a fundamental characteristic of GHRH-based therapies — the effect is dependent on continued GH axis stimulation. It is not a cure for visceral adiposity but a maintenance therapy that, when continued, sustains meaningful VAT reduction.

For the first decade of tesamorelin's existence, the evidence base was entirely confined to HIV-infected patients with lipodystrophy. That changed in 2023 with the publication of the Dhindsa et al. trial in the Annals of Internal Medicine — the first adequately powered RCT to investigate tesamorelin specifically in non-HIV adults with NAFLD. ^[4]

In 88 non-HIV adults with NAFLD randomized to tesamorelin 2mg/day or placebo for 26 weeks, the results were significant:

• Hepatic fat (measured by MRI-PDFF, the most sensitive non-invasive liver fat measurement) was significantly reduced in the tesamorelin group vs placebo
• Visceral adipose tissue decreased significantly vs placebo
• IGF-1 rose as expected, confirming GH axis engagement
• The metabolic profile improvement was meaningful in a population without HIV — demonstrating that the drug's mechanism works independently of antiretroviral therapy or HIV-related metabolic disruption

This is a pivotal finding for understanding tesamorelin's broader therapeutic potential. NAFLD (increasingly reclassified as MASLD — metabolic dysfunction-associated steatotic liver disease) affects an estimated 25% of the global adult population and represents one of the largest unmet needs in hepatology. Tesamorelin's ability to reduce both visceral fat and liver fat through a single mechanism — GH axis stimulation — positions it as a candidate for NAFLD intervention research in a non-HIV context, though it is not yet FDA-approved for this indication. ^[4,5]

For researchers sourcing tesamorelin, quality standards require third-party HPLC purity verification, mass spectrometry identity confirmation, and endotoxin testing specific to the 2mg peptide. Given tesamorelin's structural complexity as a 44-amino-acid analogue, synthesis quality and purity verification are particularly important:

In the landscape of research peptides targeting body composition, tesamorelin occupies a singular position: it is the only compound with multiple Phase 3 randomized controlled trials using CT-measured visceral fat as the primary endpoint, the only peptide with FDA approval specifically for visceral fat, and as of 2023, the first GHRH analogue with RCT evidence for visceral and liver fat reduction in a non-HIV metabolic disease population. The 15–18% VAT reduction documented across three independent trials is not marginal — it is clinically meaningful in terms of cardiovascular and metabolic risk reduction.

The 2025 approval of EGRIFTA WR (once-weekly formulation) addresses one of the main clinical barriers to long-term adherence, and the 2023 Dhindsa NAFLD trial opens a research avenue with enormous potential given NAFLD's global prevalence. Whether tesamorelin will ultimately receive FDA approval for NAFLD/MASLD is an open question — one that will depend on adequately powered, longer-duration trials with liver-specific outcomes. That research is ongoing.

For researchers, the tesamorelin story is a case study in what peptide research can achieve when backed by rigorous clinical methodology: a mechanistically rational compound, a tissue-specific pharmacological effect, and reproducible RCT evidence that survives independent replication. It is also a reminder of what remains to be shown — cognitive and cardiovascular endpoint trials, longer-term safety data in non-HIV populations, and combination studies with other metabolic interventions.

For related research on GLP-1 peptides and visceral fat, see our GLP-1 research guide. For GH secretagogue research including CJC-1295, see our CJC-1295 + Ipamorelin complete guide.